Three drug combo halves AIDS deaths. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Three drug combo halves AIDS deaths. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Treat Rev. 1997 Apr;(No 24):2-4. Unique Identifier : AIDSLINE AIDS/97702571

Abstract: Although a safety review board stopped ACTG 320 before its completion, the study showed that a three-drug combination could cut the mortality rate from AIDS in half. Study participants who were taking two nucleoside analog drugs were also given a protease inhibitor, and they developed half as many opportunistic infections as those on only two drugs. However, the study also showed that simply adding a protease inhibitor to a treatment regimen that was not working was not effective. The results of ACTG 320 show that the era of monotherapy is over, and that strong anti-HIV combinations designed to reduce viral load to undetectable levels is the preferred treatment.

Keywords: AIDS-Related Opportunistic Infections/PREVENTION & CONTROL Acquired Immunodeficiency Syndrome/*DRUG THERAPY/*MORTALITY Anti-HIV Agents/ADMINISTRATION & DOSAGE CD4 Lymphocyte Count *Clinical Trials Drug Therapy, Combination Female HIV Protease Inhibitors/ECONOMICS/*THERAPEUTIC USE Human Indinavir/*THERAPEUTIC USE Male Patient Selection United States Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLE
970830
M9781180

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .